Atul Deshpande, Harbour BioMed chief strategy officer & head, US operations (Harbour BioMed)

An­oth­er biotech IPO set-up? Multi­na­tion­al biotech leaps from round to round, scoop­ing up cash at a blis­ter­ing pace

A short four months af­ter an­nounc­ing a $75 mil­lion haul in Se­ries B+ fundrais­ing, the multi­na­tion­al biotech Har­bour Bio­Med pulled in an­oth­er round of in­vest­ments and eclipsed the nine-dig­it mark in the process.

Har­bour com­plet­ed its Se­ries C fi­nanc­ing, the com­pa­ny an­nounced Thurs­day morn­ing, rais­ing $102.8 mil­lion and bring­ing its to­tal in­vest­ment sum to over $300 mil­lion since its found­ing in late 2016. The biotech plans to use the mon­ey to tran­si­tion ear­ly-stage can­di­dates from the dis­cov­ery phase, fund can­di­dates al­ready in the clin­ic, and prep late-stage can­di­dates for com­mer­cial­iza­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.